Company intelligence / Profile preview

HG&H Pharmaceuticals

South Africa

Ownership: Private
Development stage: Other

Overview

HG&H Pharmaceuticals commercially supplies Zembrin, a patented and standardized Sceletium tortuosum extract, clinically studied for cognitive enhancement, mood improvement, and stress reduction. Human clinical trials have documented both safety and efficacy.

Therapeutic areas: NeurologyPsychiatry
Modalities: Botanical extractSmall molecule
Industry: Biotech

Drug pipeline

1 asset

Zembrin

Unknown

Partnerships

Distribution partnerships in 8 countries with 7 companiesFormal benefit-sharing agreement with South African San Council

Beyond the preview

Go deeper on HG&H Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HG&H Pharmaceuticals.

Explore the full profile